Global Issues in Allergy and Immunology

**Parasite infections and Allergy**

Alvaro A. Cruz, MD,a,b Philip J. Cooper, MD, PhD,b,c,d Camila A. Figueiredo, PhD,b,e Neuza A. Neves, MD, PhD,b,e Laura C. Rodrigues, MD, PhD,b,f Mauricio L. Barreto, MD, PhD.b,g

a ProAR – Faculdade de Medicina da Universidade Federal da Bahia, Salvador, Brazil - cruz.proar@gmail.com

b Social Change, Asthma and Allergy in Latin America (SCAALA) Study Group

c Institute of Infection and Immunity, St George’s University of London, London, UK - pcooper@sgul.ac.uk

d Facultad de Ciencias Medicas, de la Salud y la Vida, Universidad Internacional del Ecuador, Quito, Ecuador

e Instituto de Ciências da Saúde da Universidade Federal da Bahia, Salvador, Brazil - [cavfigueiredo@gmail.com](mailto:cavfigueiredo@gmail.com) and neuzalcantara@gmail.com

f London School of Hygiene and Tropical Medicine, London, UK - Laura.Rodrigues@lshtm.ac.uk

g Centro de Pesquisa Gonçalo Muniz, Fundação Oswaldo Cruz, Salvador, Brazil - barreto.mauricio@gmail.com

**Corresponding author:**

Alvaro A. Cruz, Professor of Medicine

ProAR - Faculdade de Medicina da Universidade Federal da Bahia

Rua Carlos Gomes, 270 - 7o andar

40060-330 Salvador - BA, Brazil

Tel.: +55 71 991985948

[cruz.proar@gmail.com](mailto:cruz.proar@gmail.com)

**Support:**

There was no specific financial support for the preparation of this manuscript. CAF, NMAN, MLB and AAC receive investigator grants from the Brazilian Research Council (CNPq).

**Abstract**

Allergic diseases are on the rise globally, in parallel with a decline in parasitic infection. The inverse association between parasitic infections and allergy, at an ecological level, suggests a causal association. Studies in humans have generated a large knowledge base on the complexity of the interrelationship between parasitic infection and allergy. There is evidence for causal links, but the data from animal models are the most compelling: despite the strong Type 2 immune responses they induce, helminth infections can suppress allergy through regulatory pathways. Conversely, many helminths may cause allergic-type inflammation including symptoms of “classical” allergic disease. From an evolutionary perspective, individuals with an effective immune response against helminths may be more susceptible to allergy. This narrative review aims to inform readers on the most relevant up to date evidences on the relationship between parasites and allergy. Experiments in animal models have demonstrated the potential benefits of helminth infection, or administration of helminth-derived molecules, on chronic inflammatory diseases, but clinical trials in humans have not so far demonstrated unequivocal clinical benefits. Nevertheless, there is sufficiently strong evidence to support the continued investigation of the potential benefits of helminth-derived therapies for the prevention or treatment of allergic and other inflammatory diseases.

**Keywords:** Allergy, asthma, parasite infection, helminths, epidemiology, pathogenesis.

**Abbreviations:**

AcK1 - a large family of ShK-related peptides

AAMΦs - alternatively activated macrophages

BmK1 - a large family of ShK-related peptides

CAMΦs - classically activated macrophages

CD11chigh DC – conventional dendritic cells

CD4+ T cells – T Helper Lymphocytes

CD4+ CD25+ FOXP3+ - regulatory T cells

CTLA-4 - inhibitory molecule cytotoxic T lymphocyte- associated antigen 4

DC – dendritic cells

ES - excretory-secretory molecules of helminths

FEV1 - Forced expiratory volume in 1 second

GWAS - Genome-wide association study

HIC – high income countries

iNOS – inducible nitric oxide synthase

LMIC – low- and middle-income countries

IL – interleukin

ILC – Innate lymphoid cells

IL2R – interleukin 2 receptor

IFNγ – interferon gama

LD - linkage disequilibrium

PBMC – peripheral blood mononuclear cells

PG – prostaglandin

SNP – single nucleotide polymorphism

SPT – skin prick test

STH – soil transmitted helminths

SWAP – *Schistosoma* soluble adult worm antigen

ST2 – IL33 receptor

sST2 – a soluble form of ST2

sIgE – specific IgE

tIgE – total IgE

Th – T helper cells

TLR –toll like receptors

TGFB - Transforming growth factor beta

TSLP - Thymic stromal lymphopoietin

Type 2 immune response – pattern of immune response including the Th2 cells (CD4+ cells), ILC2s and other to the cytokine milieu formerly related exclusively to Th2 activation

WHO – World Health Organization

**Outline**

1. Introduction
2. Global trends in parasite infections and allergy
   1. Global trends
   2. Epidemiological evidence for associations between parasites and allergy
3. Host immune responses against parasites
4. Commonalities between the immune response to parasites and allergy
5. Genetic determinants of protection against helminths and risk of allergy
   1. Variants that affect T helper (Th) 2 immune response
   2. Variants that affect immune regulatory mechanisms
6. Immunoregulation by helminths and clinical practice
7. Exploring the immunomodulatory potential of helminths and helminth molecules
   1. Helminth infection and immunomodulation of diseases
   2. Tests with helminth molecules as immunomodulatory candidates
8. Discussion
9. Conclusions

**Introduction**

The frequency of allergic disease has been rising in urban and urbanizing populations,1 while an overall decline in rates of infections has been observed. Studies of the inverse association between parasitic infections and allergy suggest the existence of a causal link.

While humans can be infected with some 300 species of worms and over 70 species of protozoa2 we will focus on soil-transmitted helminths (STH) also called geohelminths. Worldwide, it is estimated 1.5 billion humans are infected with one of these species.3 We will also refer to *Schistosoma* *spp*., that infect humans through contact of skin with water infested with larvae and it is estimated to infect 230 million people.4

For example, Figure 1 shows typical features of a rural household in a village of Conde, Northeast Brazil, from 2005, in which the prevalence of helminth infections was 83.5%.5 In the City of Salvador, 185 km away, the frequency of helminth infection among children was below 20%.6 An ecological study including all Brazilian municipalities reported hospitalization rates due to asthmawere lower in those endemicfor *S. mansoni* or for STH parasites.7 A typical urban underserved neighborhood of Salvador, is presented in Figure 2.

Insert Figure 1.

Typical features of a rural household in a village in the municipality of Conde, Northeast Brazil

Insert Figure 2.

Typical urban underserved neighborhood of Salvador, Northeast Brazil

The purpose of this narrative review is to inform clinicians and researchers on the most current evidence on the interrelationship between parasitic infections and allergy, from epidemiological studies to mechanisms and molecules identified in helminths, that are candidates for novel therapeutics.

**Global trends in parasite infections and allergy**

*Global trends*

Allergic diseases are among the most common chronic diseases1 particularly in populations undergoing urbanization.8 Individual risk of allergy is considered to reflect a complex interaction between genetic predisposition and environmental exposures over the life course.9 Geographic differences in the prevalence of allergy, between and within populations, is more likely to reflect exposures to common environmental factors that may either increase or decrease risk. The most consistent environmental exposures considered to reduce risk of allergy, are those associated with rural residence and include farming, animal exposures10 and infections with parasites.11

Protective immunity against STHs is mediated through Type 2 immune mechanisms11 and parasites can survive to cause chronic infections by modulating these allergic inflammatory responses. The prevalence of STH infections is declining worldwide. This reflects a combination of factors leading to reductions in transmission of these infections, including reductions in extreme poverty and improvements in the living environment (potable water and disposal of feces) and the wide availability of anthelmintic drugs. Reductions in STH prevalence, while beneficial, might raise concerns in case of being causally associated with allergy.

*Epidemiological evidence for associations between parasites and allergy*

There is evidence in support of protection against allergy by STH infections, but many studies in human populations present discordant effects.

Meta-analyses of observational studies have shown differences in effects on asthma symptoms for different parasites: while *A. lumbricoides* was associated with an increased risk of asthma, hookworm infection was associated with a reduced risk.12 In contrast, studies that have measured the presence of *Ascaris*-specific IgE - recommended by some as a marker of infection in areas of low prevalence13 but perhaps more appropriately used as a marker of allergic sensitization to *Ascaris* - have shown consistently positive associations with asthma symptoms and even disease severity.14,15

In the case of atopy, generally measured by allergen skin prick test (SPT) reactivity, most cross-sectional studies have shown inverse associations with STH infections.16 A meta-analysis of cross-sectional studies showed that current STH infections were protective against atopy, an effect that was consistent for all 3 of the most common STH infections and also schistosomiasis.16 While Ascaris infections may be inversely associated with atopy, it is often directly associated with wheezing as mentioned in the previous paragraph. STH infections are not alone in attenuating atopy. A cross-sectional study showed that several different childhood infections were independently and inversely associated with reactivity to SPT, including visceral worm *Toxoplasma gondii*, *Herpes simplex* and Epstein-Barr virus infections.6 This observation raises the possibility that rather than mediating protection directly, STH infections might be markers of poor environmental conditions that mediate protection through alternative mechanisms. Interestingly, in the study mentioned above, *T. gondii* was the only organism associated with a reduction in allergen-specific IgE in this population.6

Few prospective studies have explored the effects of geohelminths on the development of allergy. It has been suggested that the key effects of protective environmental exposures occur during early life, during which there may be a limited window of opportunity for such exposures to mediate their effects.9 If this is the case, prospective studies of the effects of STH infections on allergy should start in early childhood, ideally before birth, to measure any potential *in utero* effects of maternal STH infections. Four such prospective studies have been published to date: i) a birth cohort in Ethiopia where the prevalence of helminthiasis was considered to be too low to explore effects on wheeze and eczema to 5 years;17 ii) an observational analysis, within a randomized-controlled trial of anthelmintic treatment during pregnancy, showed that maternal and childhood hookworm and childhood *T. trichiura* were associated with a reduced risk of eczema at 5 years;18 iii) a prospective study showed that *T. trichiura* infections, during the first 5 years of life, were associated with a reduced risk of SPT in later childhood;19 and iv) a birth cohort, in a rural area, did not show an effect of maternal STH infections on SPT, wheeze, or eczema during the first 3 years of life,20 but follow-up of the cohort is in progress to determine if childhood infections may affect risk of allergy at school age.21

Another way used to test the causal link has been the interventional studies, in which the protective exposure (i.e. STH) is removed through anthelmintic treatment, thus intended to reverse any existing effects. If helminths are truly protective, one might expect to observe an increase in the prevalence of allergy in the group receiving treatment. Several intervention studies have inconsistent findings.22,23,24 None of the studies were able to show an effect on the prevalence of asthma symptoms, one showed that a single dose of anthelmintic drugs given during the latter part of pregnancy was associated with an increased risk of eczema in infancy,22 and two showed an increase in either the incidence23 or frequency24 of positive SPT after at least 1 year of treatments.

Overall, the evidence suggests that *A. lumbricoides* infection and particularly *Ascaris*-specific IgE is associated with an increased risk of asthma symptoms, in endemic areas, and that STH infections may reduce the prevalence of positive SPT, but not specific IgE (sIgE) to aeroallergens. There is still very limited evidence that STH infections protect against allergic symptoms in human populations, and the effects of early life exposures to STH infections on the development of allergy in childhood, either through maternal or childhood infections, is still insufficiently studied.

In case of schistosomiasis, all published studies have been cross-sectional showing an inverse association between *Schistosoma mansoni* infection and SPT reactivity to common aeroallergens in most cases16. A recent study in Uganda was unable to demonstrate an association between *S. mansoni* infection and wheeze, but an earlier study in Brazil showed that *S. mansoni* infection was associated with a milder form of asthma.25

Insert Figure 3.

Schematic representation summarizing the findings from epidemiological studies of the relationships between helminth parasites, atopy and asthma

**Host immune response against parasites**

Helminths are the largest organisms to infect vertebrate hosts, leading to the release of large quantities of parasite molecules that interact with the immune system. It might be expected that helminth infections should induce an overwhelming immune response, resulting in the elimination of the parasites, while causing potentially damaging inflammation. However, co-evolution of hosts and parasites over millennia has allowed both host and parasite to survive through the development of mechanisms that dampen the host inflammatory response to the parasite or even allow the parasite to evade the host immune response, resulting in infections that are often asymptomatic.11 For example, *Schistosoma spp* adults, that live within the human vascular system, can survive for many years without inducing strong host inflammatory responses.26

Although the most widely studied host immune response against helminths is the acquired Th2-type response, we shall discuss both innate and adaptive host immune responses to helminth parasites. The Th2 type response is characterized by the production of high levels of the cytokines *IL4, IL5, IL9, IL10, IL13, IL21, IL33*. These cytokines orchestrate immediate hypersensitivity that involves B cell class switching to IgG4 and IgE, eosinophilia, goblet cell hyperplasia and mastocytosis, alternative activation of macrophages, and the influx of inflammatory cells such as eosinophils that contribute to parasite killing. Such a response may control parasite numbers by killing them in tissues or expelling them from the intestinal lumen. The host response to helminth infections is associated with allergic phenomena that are a consequence of killing, or an attempt to kill or expel, these parasites.27 Examples are shown in Table 1.

Although helminth parasites are universal in inducing all, or most of these Th2 effector pathways, in the host, the specific effector pathway mediating protection varies between different parasites, life cycle stages, and site of infestation. For example, the intestinal helminths *Heligmosomoides polygyrus* and *Trichinella spiralis*, are expelled from the intestinal lumen by several Th2 effector pathways such as IgE-mediated activation of mucosal mast cells. Th1 responses may also have a role in protective immunity against some helminth parasites such as *S. mansoni* infection,28  while the control of parasite burden in strongyloidiasis is highly dependent on Type 2 responses.29

One of the parasite’s first contact with the host’s immune system is through CD11chigh DC, which undergo alternative activation, for example in response to excretory-secretory (ES) molecules from the murine intestinal helminth parasites *Heligmosomoides polygyrus* and *Nippostrongylus brasiliensis*.30 Helminth molecules bind to TLR2, 3, 4 receptors on the dendritic cell membrane driving the acquired immune response from naive Th0 to a Th2 profile.31

An important group of innate immunity cells, the innate lymphocyte (ILCs), which lack B or T cells antigen specific receptors, and do not express myeloid or dendritic cell markers, has been shown to comprise three sub-sets: ILC1 (related to T1 profile), ILC2 (related to T2) and ILC3 (related to ThI7).32 ILC2 produce a large set of T2 cytokines (IL4, IL5, IL9, IL13 and IL21) in response to stimulation with IL25, IL33 and TSLP32 and play an important role in protection against helminths. However, unlike Th2 cells, ILC2 are stimulated by alternatively activated macrophages (AAMΦs), express MHC-II, and are able to endocytose and process antigen.33 AAMΦs are phenotypically distinct from classically activated macrophages (CAMΦs) that are typical of Th1 type responses. AAMΦs do not produce IFNγ and instead of inducible nitric oxide synthase (iNOS), have upregulated expression of Arginase-1 that has higher affinity for arginine, competing with iNOS present in CAMΦs. AAMΦs are induced during infections with several helminth parasites.34 Interestingly, an interaction between ILC2 and Th2 cells for maintaining AAMΦs in lungs of hookworm-infected mice has been reported.35

Other immune cells reported to play a role in immunity against helminth infection are the Th17, derived from CD4(+) T cells after antigen maturation. Th17 cells are important for the clearance of several extracellular pathogens, such as bacteria and helminths.36 In *S. japonicum*-infected mice, there was an increase in Th17 cells following granuloma development, attributed to the presence of induced factors (e.g. TGFB, IL23 and IL21) in greater amounts than inhibitory factors (e.g. Treg and T2 cells, and IL-4).37

Helminths have developed several mechanisms to suppress or avoid host anti-parasite responses. For example, *S. mansoni* has developed parasite stage-specific evasion strategies. Entry of cercariae through the skin is followed by the release of larval excretory-secretory molecules of helminths (ES) products (e.g. PGD2) that cause host cells to release PGE2.38 Both host and parasite-derived prostaglandins induce the production of *IL10* in the skin that inhibits the migration of epidermal Langerhans cells to the invasion site.39

The most remarkable evasion strategy used by helminths, particularly those dwelling within host tissues and in blood and lymphatic systems, is the down-modulation of the host immune system leading to a form of immunologic tolerance that, itself, may have effects on host responses to other infections and allergy. The cells mediating this effect are the Treg sub-set of the CD4+ T lymphocytes that produce the immune modulatory cytokines IL10 and TGFB. The presence of regulatory cells is associated with a reduction in Th2 cells and the development of a modified type 2 immune response. Other cells involved are AAMΦs and B-regulatory cells.11

**Commonalities between the immune response to parasites and allergy**

The host immune response to helminth parasites has many features in common with allergy. Bronchial inflammation of atopic asthma is coordinated by cells of the adaptive immune system, but also by ILC2 of the innate response, which together induce a Type 2 response.40 During helminth infections Type 2 immunity is initiated at the site of parasite invasion by epithelial cells, which release the alarmins IL25 and IL33 to prompt ILCs to produce IL13 and other cytokines that are also involved in the pathoetiology of asthma. In the absence of either IL25 or IL33, resistance to helminth infections is severely impaired.41 Tregs cells have a dual role in helminth infections: they protect the host from excessive inflammatory responses during infection, but they also may decrease protective immunity and, thereby, permit parasite persistence.42 In the case of asthma, several studies have shown allergic patients to have lower numbers of Tregs in both the bronchoalveolar lavage and peripheral blood monocytes cells (PBMC).43 Thus, there are notable parallels between the immune responses associated with allergy and those observed in response to helminth infection.

Host Type 2 immune responses to parasites and allergens are induced by a limited number of protein families that contain allergens such as tropomyosins.14 There is extensive structural homology between allergens from helminths and other environmental sources.44 Further, allergen homologues derived from parasites and aeroallergens do not just exhibit IgE cross-reactivity but can also induce cross-sensitization in murine models.45 Cross-reactivity between helminths and aerollergens has a number of important consequences including false-positive reactions for specific IgE when used in the diagnosis of allergy and also a potential increase in morbidity caused by inflammatory reactions directed against cross-reactive allergens. In the case of the latter, cross-reactivity could help drive the exaggerated responses associated with inflammatory syndromes that have been reported in human helminth infections such as tropical pulmonary eosinophilia in the case of lymphatic filariasis46 and Loeffler’s syndrome in ascariasis.47 Likewise, it has been suggested that immune modulation during chronic helminth infections, which subvert Th2-mediated inflammation permitting parasite survival, could affect atopic responses to common aeroallergens through either bystander effects or immunological cross-reactivity.45

Insert Figure 4.

Helminths suppress autoimmunity and allergy via Type 2 or regulatory immune response.48

**Genetic determinants of protection against helminths and risk of allergy**

Characterization of parasite genomes and subsequent comparison of parasites to more complex species, such as mammalian hosts, have contributed to our understanding of the mechanisms of parasite evolution and have provided evidence for the role of host–parasite interaction in genetic adaptation. An understanding of that genetic adaptation has elucidated candidate genes, which may drive susceptibility to other diseases of the immune system, including atopy and asthma.49 Thus, genetic variants affecting any of the classical key-roles inflammation inducing factors, as well as proteins related to controlling inflammation through immune regulatory mechanisms such as Treg, may play a role on both helminth resistance and allergic conditions. Genetic studies have highlighted common variants [Minor allele frequency (MAF) >10-30%] that affect allergy in many different ways. In Figure 5, an analysis using the Protein ANalysis THrough Evolutionary Relationships (PANTHER) version 1150 is presented showing different pathways related to the main genes described in genome-wide association studies (GWAS) to date, in which one may observe 3 out of the top 4 pathways linked to asthma are related to interleukin signaling and inflammation.

The genetic variants that affect protection against helminths and risk of allergy, can be organized in two main groups: those affecting Th2 immune response and those affecting regulatory mechanisms.

Insert Figure 5:

Pathway analysis using Panther 11 version for the top single nucleotide polymorphisms (SNPs) associated in GWAS for asthma to date.

*Variants that affect Th2 immune response*

Common genetic variants of Type 2 immune signaling relating to allergy and asthma, provide credence to the hypothesis that the origin of these allergy-promoting variants derives from evolutionary mechanisms and their selection occurred in the presence of widespread, endemic helminth infection.51 A region on chromosome 5, 5q31-q33, for example, has been associated with resistance to *S. mansoni* through the presence of genes such as those of granulocyte-macrophage factor (*CSF2*), *IL3*, *IL4*, *IL5* and *IL13*, that are important in protective immunity against *S. mansoni*.52 The same locus (5q31-q33) has been linked to asthma and atopy. Other relevant loci that are also linked to asthma are 7q and 21q.53

In terms of asthma susceptibility, several immune molecules have been associated with asthma/allergy. In both GWAS and candidate genes studies some 200 genes have been associated with asthma or related phenotypes. Among these genes, there are those related to a possible modulation of plasma tIgE levels.54 Association studies of genes encoding the epithelial cell-derived cytokines, *IL33* and *TSLP*, and the *IL1RL1* gene encoding the *IL33* receptor, ST2, highlight the central roles for innate immune response pathways that promote the activation and differentiation of Th2 cells. These genes are the most consistent variants associated with asthma, allergy and helminth infections across ethnically diverse populations.55

In this context, GWAS studies for allergic diseases have pinpointed *IL33* and *IL1RL1* as key susceptibility genes for allergic asthma, underscoring the pivotal role of this pathway in the pathophysiology of this diseases.56 Studies involving the genes codifying the *IL33/ST2* route have been widely replicated in different populations,57 confirming their association with asthma58 and blood eosinophilia.59 The mechanism whereby the *IL33/ST2* axis induces Th2-inflammation was demonstrated recently.60 Local airway soluble ST2 (sST2) levels, as well as circulating plasma sST2 levels, contribute to neutralization of *IL33* in the tissues.

The role of human genetic determinants of *IL33/ST2* in helminth infection is poorly understood. Using a generalized estimating equation model, three SNPs associated with higher *Schistosoma* soluble adult worm antigen (SWAP) specific IgE/IgG4 (a measure of resistance to *S. mansoni*) were found.61 The most significant SNP mapped to intron 1, and the allele, which has been shown to confer asthma risk in an African-American population, also conferred protection against schistosomiasis.

Major polymorphisms within the 5q31-q33 genomic region, previously associated with resistance to *S. mansoni* infection have been studied.52,53 The region includes several genes related to immune function including *IL4, IL5*, and *IL13* genes in the Th2 cluster. Resistance to *S. haematobium* was associated with the *IL13*-1055T/T genotype62 which has also been implicated in asthma exacerbations.63 Further, a functional *IL13* polymorphism, rs1800925T, was shown to contribute to the risk of late-stage schistosomiasis caused by *S. japonicum*.64 In another study, two quantitative traits, tIgE levels (representing Th2 pathway activation) and *S. mansoni* egg counts, that reflect host immunity to helminths were investigated, providing a unique opportunity for the genetic dissection of the Th2 pathway in the context of schistosomiasis.7 Significant associations were seen between two functional variants on the *IL13* gene and *S. mansoni* egg counts, indicating *IL13* to be protective, but no associations of *IL13* gene variants with tIgE levels. Since the functional effect of both variants on the gene product, *IL13*, is to increase its amount or activity, this finding suggests *IL13* functions to increase anti-helminth immunity, and functional variants may be an evolutionary vestige of selective forces that may now favor atopic phenotypes.5

*Variants that affect immune regulatory mechanisms*

Alterations in regulatory cytokine levels are believed to play an important role in mediating immune suppression in helminth immune response. Genetic variants affecting *IL10* and *TGFB1* may be associated with both asthma/allergy and heminthiasis. We described a variant (rs3024496, G allele) in the *IL10* gene associated with the suppression of *IL10* production in *A. lumbricoides* antigen-stimulated cultures of peripheral blood leukocytes, and also, other variants within the same gene, were both positively associated with atopy and asthma and negatively associated with helminth co-infections.65

Several *IL10* promoter polymorphisms have been extensively studied. Some variants were significantly associated with high PBMC proliferative responses to *Onchocerca volvulus* antigen.66 One of these promoter variants, the G-1082A was also associated with immune-related diseases including type 2 diabetes, multiple sclerosis, and asthma.67 Moreover, the same variant was associated with pediatric asthma.68 In an endemic area for *S. mansoni* alleles at the three promoter SNPs were associated with high tIgE levels in the same direction as in atopic individuals, but not with egg counts. *IL10* promoter polymorphisms appear to influence non-specific tIgE levels, but not schistosomiasis-specific immunity.7

Genetic polymorphisms in *TGFB1* are associated with airway responsiveness and exacerbations in children with asthma.69 Common variants in *TGFB1* gene affect both asthma/allergy and helminth infections. We demonstrated a negative association between rs1800470 (C allele), atopic wheezing and markers of allergy. In contrast, a positive association was observed between the haplotype ACCA and *T. trichiura* and *A. lumbricoides* infection. This later haplotype was also associated with increased *IL10* production.70

The main cellular source of both *IL10* and *TGFB1* are Tregs, critical for the maintenance of immune homeostasis. The activation of FOXP3 transcriptional factor is pivotal for Tregs function. The human FOXP3 gene is located on the X-chromosome (Xp11.23) and because of sex differences among X-variants, insufficient efforts have been made to include X variants in GWAS. Polymorphisms in the FOXP3 gene have been evaluated in association studies for allergy71 but only a few studies on asthma have been reported. A study reported a significant interaction between SNPs in FOXP3-IL2R genes and sIgE for worm eggs and asthma.72 The SNPs rs2294019 and rs5906761 were associated with the risk of egg sensitization only in females.71 The heterozygote genotype for rs3761547 was a risk factor for allergic rhinitis, and this association was reproduced in gene-gene interaction analysis with rs3761548.72

The immune regulation of allergic disease results not only from protective environmental factors including helminths, but also from genetic factors relating to *IL10* production or hyperactivation of Type 2 immune responses. From an evolutionary perspective, the selective advantage acquired by humans able to mount an efficient protective immune response to helminth infections may make them more vulnerable to atopy and asthma.

**Immunoregulation by helminths and clinical practice**

Insert Table 1.

Examples of helminth infections and the allergic-type inflammatory responses with which they are associated.

Treatment of allergic diseases with systemic corticosteroids at immunosuppressive doses increase the risk of opportunistic infections. The helminth reported to affect immune suppressed hosts most frequently is *Strongyloides stercoralis,* occasionally resulting in uncontrolled dissemination of the parasite in the potentially fatal hyper-infection syndrome. *Strongyloides* hyperinfection has been associated also with other immunosuppressive drugs, lymphomas, and infection with HTLV-1 virus.73 Because of the presumed central role of IgE in protective immunity against helminth parasites, treatment of severe asthma with anti-IgE antibody raised concerns about risk of severe or disseminated helminth infections. A multicentre randomized controlled trial of omalizumab for the treatment of asthma and rhinitis was safe in a population at risk of STH infections, although there was a modest increase in geohelminth infection.74 The same safety concerns will be present, in populations at risk of helminthiasis, for other immunomodulatory compounds for treatment of allergic diseases, particularly those targeting specific Type 2 effector pathways such as anti-*IL5* and anti-*IL13/IL4*.

Helminth infections induce cellular immune hyporesponsiveness.11 Such hyporesponsiveness has been associated with suboptimal vaccine responses.75,76 Among pregnant women, soluble parasite antigens cross the placenta and modify fetal immune responses in such a way as to possibly affect vaccine responses in childhood.77 Modification of the host immune response to helminths affects how humans respond immunologically to other pathogens such as those causing malaria78 and tuberculosis,79 however, effects on clinically measurable outcomes are less clear.

Insert Clinical Notes I.

Notes of relevance for clinical allergy practice on immunopathology of helminth infections.

Reports have indicated possible benefits of helminth infections on autoimmune diseases, inflammatory bowel disease, and even in the metabolic syndrome.80 For example, an inverse association between lymphatic filariasis and type II diabetes was reported,81 and past infection with *S. japonicum* was associated with a lower prevalence of metabolic syndrome.82 Intestinal helminth infections were inversely associated with risk factors for cardiovascular diseases, such as body mass index and lipid levels.83

Insert Clinical Notes II.

Notes of relevance on protection against allergy and other chronic diseases.

**Exploring the immunomodulatory potential of helminths and helminth molecules**

*Helminth infection and immunomodulation of diseases*

An observational study of patients with multiple sclerosis, who had acquired gastrointestinal helminth infections, reported remission of multiple sclerosis for over 4 years. Patients infected with parasites had reduced inflammatory cytokine responses and enhanced production of *IL10* as well as *TGFB*. Six of these subjects were followed up and remission continued into the sixth year, when four patients were offered anthelmintic treatment due to gastrointestinal problems. Subsequently their multiple sclerosis activity resumed while *IL10* and *TGFB* levels declined.84

Experimental infections of humans with live parasites employing either the pig whipworm, *T suis*, or the human hookworm, *N. americanus,* have been reported.85 The premise is that the immune system can be modulated with amelioration or remission of the inflammatory disease. In the case of treatment with *T. suis*, parasite eggs are administered orally. Initial studies reported a beneficial effect on Crohn’s disease and ulcerative colitis.86 *T. suis* eggs have been used to treat other immune disorders. A randomized controlled trial tested the efficacy of *T. suis* for the treatment allergic rhinitis in Denmark but showed no efficacy. Although *T. suis* infection generated a measurable anti-parasite response, infection did not affect allergen-specific responses.87 Patients with Crohn’s disease were infected with *N. americanus*, with the majority showing improvements in symptom scores.88 A trial of *N. americanus* in patients with coeliac disease was unable to demonstrate clinical benefit.89 A small randomized control trial in patients with asthma showed no significant benefit of hookworm infection on clinical symptoms, bronchial responsiveness or SPT reactivity.90

What may be the reasons for the disappointing findings of clinical trials to date? Experimental animal models have demonstrated helminth parasites reduce allergic reactivity, but most studies have been designed to prevent the development of allergic reactivity rather than treat established disease. Only a handful of studies have reported the effects of these infections on already established allergic reactivity.91 Most of the experimental data available suggest that once the allergic reaction is established, helminth infections can do little to revert the disease process, raising the question whether there is any reasonable possibility of obtaining benefit through infections of individuals with active disease. Nonetheless, there are sufficient doubts with respect to optimal timing of treatment, the dose and systemic versus non-systemic infections, to justify future well-designed randomized-controlled trials of helminth therapy for inflammatory conditions.

*Tests with helminth molecules as immunomodulatory candidates*

Recombinant proteins can reproduce the biological effects observed in infections with live worms. In experimental models of inflammatory disease, recombinant proteins derived from helminth molecules induce anti-inflammatory and inhibit pro-inflammatory cytokine production, promote regulatory cell recruitment and immune deviation.92

In mouse models, helminth ES molecules, and helminth-derived synthetic molecules have shown usefulness in treating or preventing the development of inflammatory diseases such as inflammatory bowel diseases, type 1 diabetes, multiple sclerosis, rheumatoid arthritis and asthma. The synthetic production of ES-derived immune modulators avoids concerns raised by the use of live organisms.93 Further, the molecule-based helminth treatment offers the advantage of delivery directly to the site of pathology.

We present in Table 2 a summary of pre-clinical and clinical studies of helminth molecules for the treatment of chronic inflammatory conditions affecting humans.

Insert Table 2.

Helminth molecule candidates for the treatment of inflammatory diseases.

**Discussion**

There is conflicting evidence of an inverse association between exposure to helminth infections and human chronic inflammatory diseases, including allergic conditions. A possible causal relationship is supported largely by the findings from experimental animal models, while evidence from human studies has been equivocal. Evidence from clinical trials of live helminth parasites has been disappointing.

One explanation for the associations between allergy and helminths in epidemiological studies is the genetic evolutionary advantage of mounting strong Type 2 responses protective against helminth infection although increasing the risk of allergy.65 However, large increases in the prevalence of allergy have occured in a short time to be explained solely by genomic changes in human populations. This indicates the importance of environmental factors in aberrant immune reactivity. The sort of environmental and unhygienic living conditions where parasite infections are likely to occur also expose populations to multiple other microorganisms which may contribute to the modulation of inflammatory responses.94,95 Studies have demonstrated helminth infections, intestinal microbiota and nutrition are inter-related.96 Both, the intestinal microbiota and the nutrition may interact with the effects of helminth infections. Moreover, there is evidence that several other contextual factors not always controlled for in observational studies might contribute to the inverse association between helminthes and allergy. Such factors include diet, nutrition, obesity, gut microbiome, physical activity, exposure to air pollution, stress and use of vaccines and antibiotics, all of which are related to an urbanized lifestyle, which has clearly been an important risk factor for allergy.97,98

How do we interpret the negative results of clinical trials of live helminth infections when helminth infections or helminth-derived molecules have proved so effective in controlling animal models of inflammatory diseases? The effects of helminth infections in humans are related to parasite burden and duration of infection. No safety issues have been reported after administration of *Trichuris suis* ova so far, even to immune suppressed patients, but in general, there are safety and ethical concerns with treating humans with large infectious doses and maintaining infections for period of years that may be required to induce clinically relevant immune modulatory effects. Besides this, some trials in patients with inflammatory bowel disease were unable to show an immune suppressive effect of helminths due to a very high placebo response rate (unpublished). In some trials patients were continued with their immune suppressive medications, making interpretation of data on efficacy of helminth infections more difficult. Further, trials in humans have attempted to modify preexisting disease while most animal models have studied the ability of helminths to prevent disease.

**Conclusions**

There is consolidated evidence from studies in humans for a negative association of helminth infection with allergy, although the effect seems to vary by helminth species, parasite burden, and age of infection. Helminth infections may also provoke symptoms of allergy, although such allergic inflammation tends to be modulated during chronic infections. Experiments in animal models of chronic inflammatory diseases have demonstrated the potential benefits of helminth infection or the use of helminth-derived molecules against allergic disease, but clinical trials in humans have been disappointing. We still have an inadequate understanding of the complex interplay between helminths and allergy and there is a need for more studies in humans and experimental studies in animal models to understand these interactions more fully. Certainly, the exploitation of helminth-derived molecules for the treatment of inflammatory conditions offers promising new avenues for research and development.

**References**

1. Matricardi PM. The Allergy Epidemic. In: Global Atlas of Allergy. European Academy of Allergy and Clinical Immunology, 2014.
2. Ashford RW and W Crewe. 1998. The parasites of *Homo sapiens.* Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
3. World Health Organization. Soil-transmitted helminth infections. Fact sheet updated January 2017 [<http://www.who.int/mediacentre/factsheets/fs366/en/> assessed on 15 July 2017].
4. Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. Lancet. 2014 Jun 28;383(9936):2253-64. doi: 10.1016/S0140-6736(13)61949-2.
5. Grant AV, Araujo MI, Ponte EV, Oliveira RR, Cruz AA, Barnes KC, et al. High heritability but uncertain mode of inheritance for total serum IgE level and *Schistosoma mansoni* infection intensity in a schistosomiasis-endemic Brazilian population. *J Infect Dis.* 2008 Oct 15;198(8):1227-36. doi: 10.1086/591946.
6. Alcantara-Neves NM, Veiga RV, Dattoli VC, Fiaccone RL, Esquivel R, Cruz AA, et al. The effect of single and multiple infections on atopy and wheezing in children. *J Allergy Clin Immunol*. 2012 Feb;129(2):359-67, 367.e1-3. doi: 10.1016/j.jaci.2011.09.015.
7. Ponte EV, Rasella D, Souza-Machado C, Stelmach R, Barreto ML, Cruz AA. Reduced asthma morbidity in endemic areas for helminth infections: a longitudinal ecological study in Brazil. J Asthma. 2014 Dec;51(10):1022-7. doi: 10.3109/02770903.2014.936454.
8. Rodriguez A, Vaca M, Oviedo G, Erazo S, Chico ME, Teles C, et al. Urbanisation is associated with prevalence of childhood asthma in diverse, small rural communities in Ecuador. Thorax. 2011 Dec;66(12):1043-50. doi: 10.1136/thoraxjnl-2011-200225.
9. Burbank AJ, Sood AK, Kesic MJ, Peden DB, Hernandez ML. Environmental determinants of allergy and asthma in early life. J Allergy Clin Immunol. 2017 Jul;140(1):1-12. doi: 10.1016/j.jaci.2017.05.010.
10. von Mutius E. The microbial environment and its influence on asthma prevention in early life. J Allergy Clin Immunol. 2016 Mar;137(3):680-9. doi:10.1016/j.jaci.2015.12.1301.
11. Maizels RM, McSorley HJ. Regulation of the host immune system by helminth parasites. J Allergy Clin Immunol. 2016 Sep;138(3):666-75. doi: 10.1016/j.jaci.2016.07.007.
12. Leonardi-Bee J, Pritchard D, Britton J. Asthma and current intestinal parasite infection: systematic review and meta-analysis. Am J Respir Crit Care Med. 2006 Sep 1;174(5):514-23.
13. Fincham JE, Markus MB, van der Merwe L, Adams VJ, van Stuijvenberg ME, Dhansay MA. Ascaris, co-infection and allergy: the importance of analysis based on immunological variables rather than egg excretion. Trans R Soc Trop Med Hyg. 2007 Jul;101(7):680-2. Epub 2007 Jan 24. PubMed PMID: 17254621.
14. Ahumada V, García E, Dennis R, Rojas MX, Rondón MA, Pérez A, et al. IgE responses to *Ascaris* and mite tropomyosins are risk factors for asthma. Clin Exp Allergy. 2015 Jul;45(7):1189-200. doi: 10.1111/cea.12513.
15. Hunninghake GM, Soto-Quiros ME, Avila L, Ly NP, Liang C, Sylvia JS, et al. Sensitization to Ascaris lumbricoides and severity of childhood asthma in Costa Rica. J Allergy Clin Immunol. 2007 Mar;119(3):654-61. PubMed PMID: 17336615.
16. Feary J, Britton J, Leonardi-Bee J. Atopy and current intestinal parasite infection: a systematic review and meta-analysis. Allergy. 2011 Apr;66(4):569-78. doi: 10.1111/j.1398-9995.2010.02512.x.
17. Amberbir A, Medhin G, Erku W, Alem A, Simms R, Robinson K, et al. Effects of Helicobacter pylori, geohelminth infection and selected commensal bacteria on the risk of allergic disease and sensitization in 3-year-old Ethiopian children. Clin Exp Allergy. 2011 Oct;41(10):1422-30. doi: 10.1111/j.1365-2222.2011.03831.x.
18. Mpairwe H, Ndibazza J, Webb EL, Nampijja M, Muhangi L, Apule B, et al. Maternal hookworm modifies risk factors for childhood eczema: results from a birth cohort in Uganda. Pediatr Allergy Immunol. 2014 Aug;25(5):481-8. doi: 10.1111/pai.12251.
19. Rodrigues LC, Newcombe PJ, Cunha SS, Alcantara-Neves NM, Genser B, Cruz AA, et al. Early infection with *Trichuris trichiura* and allergen skin test reactivity in later childhood. Clin Exp Allergy. 2008 Nov;38(11):1769-77. doi: 10.1111/j.1365-2222.2008.03027.x.
20. Cooper PJ, Chico ME, Amorim LD, Sandoval C, Vaca M, Strina A, et al. Effects of maternal geohelminth infections on allergy in early childhood. J Allergy Clin Immunol. 2016 Mar;137(3):899-906.e2. doi: 10.1016/j.jaci.2015.07.044.
21. Cooper PJ, Chico ME, Platts-Mills TA, Rodrigues LC, Strachan DP, Barreto ML. Cohort Profile: The Ecuador Life (ECUAVIDA) study in Esmeraldas Province, Ecuador. Int J Epidemiol. 2015 Oct;44(5):1517-27. doi: 10.1093/ije/dyu128.
22. Mpairwe H, Ndibazza J, Webb EL, Nampijja M, Muhangi L, Apule B, et al. Maternal hookworm modifies risk factors for childhood eczema: results from a birth cohort in Uganda. Pediatr Allergy Immunol. 2014 Aug;25(5):481-8. doi: 10.1111/pai.12251.
23. van den Biggelaar AH, Rodrigues LC, van Ree R, van der Zee JS, Hoeksma-Kruize YC, Souverijn JH, et al. Long-term treatment of intestinal helminths increases mite skin-test reactivity in Gabonese schoolchildren. J Infect Dis. 2004 Mar 1;189(5):892-900.
24. Flohr C, Tuyen LN, Quinnell RJ, Lewis S, Minh TT, Campbell J, et al. Reduced helminth burden increases allergen skin sensitization but not clinical allergy: a randomized, double-blind, placebo-controlled trial in Vietnam. Clin Exp Allergy. 2010 Jan;40(1):131-42. doi: 10.1111/j.1365-2222.2009.03346.x.
25. Medeiros M Jr, Figueiredo JP, Almeida MC, Matos MA, Araújo MI, Cruz AA, et al. Schistosoma mansoni infection is associated with a reduced course of asthma. J Allergy Clin Immunol. 2003 May;111(5):947-51. PubMed PMID: 12743556.
26. Nawras M, El-Saghier Mowafy, Ekhlas Hamed Abdel-Hafeez. Schistosomiasis with special references to the mechanisms of evasion. The Journal of Coastal Life Medicine, 2015: 3(11): 914-923. doi:10.12980/jclm.3.2015j5-130.
27. Maizels RM. Parasitic helminth infections and the control of human allergic and autoimmune disorders. Clin Microbiol Infect. 2016 Jun;22(6):481-6. doi:10.1016/j.cmi.2016.04.024.
28. Anthony RM, Rutitzky LI, Urban JF Jr, Stadecker MJ, Gause WC. Protective immune mechanisms in helminth infection. Nat Rev Immunol. 2007 Dec;7(12):975-87. Review. PubMed PMID: 18007680; PubMed Central PMCID: PMC2258092.
29. Porto AF, Neva FA, Bittencourt H, Lisboa W, Thompson R, Alcântara L, et al. HTLV-1 decreases Th2 type of immune response in patients with strongyloidiasis. Parasite Immunol. 2001 Sep;23(9):503-7. PubMed PMID: 11589779.
30. Cook PC, Jones LH, Jenkins SJ, Wynn TA, Allen JE, MacDonald AS. Alternatively activated dendritic cells regulate CD4+ T-cell polarization in vitro and in vivo. Proc Natl Acad Sci U S A. 2012 Jun 19;109(25):9977-82. doi:10.1073/pnas.1121231109.
31. Carvalho L, Sun J, Kane C, Marshall F, Krawczyk C, Pearce EJ. Review series on helminths, immune modulation and the hygiene hypothesis: mechanisms underlying helminth modulation of dendritic cell function. Immunology. 2009 Jan;126(1):28-34. doi: 10.1111/j.1365-2567.2008.03008.x.
32. Smith KA, Harcus Y, Garbi N, Hämmerling GJ, MacDonald AS, Maizels RM. Type 2 innate immunity in helminth infection is induced redundantly and acts autonomously following CD11c(+) cell depletion. Infect Immun. 2012 Oct;80(10):3481-9. doi: 10.1128/IAI.00436-12.
33. Oliphant CJ, Hwang YY, Walker JA, Salimi M, Wong SH, Brewer JM, et al. MHCII-mediated dialog between group 2 innate lymphoid cells and CD4(+) T cells potentiates type 2 immunity and promotes parasitic helminth expulsion. Immunity. 2014 Aug 21;41(2):283-95. doi: 10.1016/j.immuni.2014.06.016.
34. Kreider T, Anthony RM, Urban JF Jr, Gause WC. Alternatively activated macrophages in helminth infections. Curr Opin Immunol. 2007 Aug;19(4):448-53. Epub 2007 Aug 16. Review. PubMed PMID: 17702561.
35. Bouchery T, Kyle R, Camberis M, Shepherd A, Filbey K, Smith A, et al. ILC2s and T cells cooperate to ensure maintenance of M2 macrophages for lung immunity against hookworms. Nat Commun. 2015 Apr 27;6:6970. doi:10.1038/ncomms7970.
36. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005 Nov;6(11):1123-32. Epub 2005 Oct 2. PubMed PMID: 16200070.
37. Wen X, He L, Chi Y, Zhou S, Hoellwarth J, Zhang C, et al. Dynamics of Th17 cells and their role in Schistosoma japonicum infection in C57BL/6 mice. PLoS Negl Trop Dis. 2011 Nov;5(11):e1399. doi:10.1371/journal.pntd.0001399.
38. He YX, Chen L, Ramaswamy K. *Schistosoma mansoni, S. haematobium*, and *S. japonicum*: early events associated with penetration and migration of schistosomula through human skin. Exp Parasitol. 2002 Oct;102(2):99-108.
39. Angelim V, Faveeuw C, Roye O, Fontaine J, Teissier E, Capron A, et al. Role of the parasite-derived prostaglandin D2 in the inhibition of epidermal Langerhans cell migration during schistosomiasis infection. J Exp Med. 2001 May 21;193(10):1135-47. PubMed PMID: 11369785.
40. Robinson D, Humbert M, Buhl R, Cruz AA, Inoue H, Korom S, et al. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017 Feb;47(2):161-175. doi: 10.1111/cea.12880.
41. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010; 464:1367-70. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010; 464:1367-70.
42. Sawant DV, Gravano DM, Vogel P, Giacomin P, Artis D, Vignali DA. Regulatory T cells limit induction of protective immunity and promote immune pathology following intestinal helminth infection. J Immunol 2014; 192:2904-12.
43. Hartl D, Koller B, Mehlhorn AT, Reinhardt D, Nicolai T, Schendel DJ, et al. Quantitative and functional impairment of pulmonary CD4+CD25hi regulatory T cells in pediatric asthma. J Allergy Clin Immunol 2007; 119:1258-66.
44. Tyagi N, Farnell EJ, Fitzsimmons CM, Ryan S, Tukahebwa E, Maizels RM, et al. Comparisons of Allergenic and Metazoan Parasite Proteins: Allergy the Price of Immunity. PLoS Comput Biol. 2015 Oct 29;11(10):e1004546. doi: 10.1371/journal.pcbi.1004546.
45. Santiago Hda C, Nutman TB. Role in Allergic Diseases of Immunological Cross-Reactivity between Allergens and Homologues of Parasite Proteins. Crit Rev Immunol. 2016;36(1):1-11. doi: 10.1615/CritRevImmunol.2016016545.
46. Gazzinelli-Guimarães PH, Bonne-Année S, Fujiwara RT, Santiago HC, Nutman TB. Allergic Sensitization Underlies Hyperreactive Antigen-Specific CD4+ T Cell Responses in Coincident Filarial Infection. J Immunol. 2016 Oct 1;197(7):2772-9. doi: 10.4049/jimmunol.1600829.
47. Gelpi AP, Mustafa A. Seasonal pneumonitis with eosinophilia. A study of larval ascariasis in Saudi Arabs. Am J Trop Med Hyg. 1967 Sep;16(5):646-57. Review. PubMed PMID: 4861323.
48. Finlay CM, Walsh KP, Mills KH. Induction of regulatory cells by helminth parasites: exploitation for the treatment of inflammatory diseases. Immunol Rev. 2014 May;259(1):206-30. doi: 10.1111/imr.12164.
49. Barnes KC, Grant AV, Gao P. A review of the genetic epidemiology of resistance to parasitic disease and atopic asthma: common variants for common phenotypes? Curr Opin Allergy Clin Immunol 2005; 5:379-85.
50. Mi H, Huang X, Muruganujan A, Tang H, Mills C, Kang D, et al. PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements. Nucleic Acids Res 2017; 45:D183-D9.
51. Hopkin J. Immune and genetic aspects of asthma, allergy and parasitic worm infections: evolutionary links. Parasite Immunol 2009; 31:267-73.
52. Marquet S, Abel L, Hillaire D, Dessein H, Kalil J, Feingold J, et al. Genetic localization of a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33. Nat Genet 1996; 14:181-4.
53. Marquet S, Abel L, Hillaire D, Dessein A. Full results of the genome-wide scan which localises a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33. Eur J Hum Genet 1999; 7:88-97.
54. Forno E, Wang T, Yan Q, Brehm J, Acosta-Perez E, Colon-Semidey A, et al. A Multi-omics Approach to Identify Genes Associated with Childhood Asthma Risk and Morbidity. Am J Respir Cell Mol Biol. 2017 Jun 2. doi: 10.1165/rcmb.2017-0002OC.
55. Oboki K, Ohno T, Kajiwara N, Saito H, Nakae S. IL-33 and IL-33 receptors in host defense and diseases. Allergol Int 2010; 59:143-60.
56. Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, et al. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med 2010; 363:1211-21.
57. Allakhverdi Z, Smith DE, Comeau MR, Delespesse G. Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 2007; 179:2051-4.
58. Smith DE. IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin Exp Allergy 2010; 40:200-8.
59. Gudbjartsson DF, Bjornsdottir US, Halapi E, Helgadottir A, Sulem P, Jonsdottir GM, et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet 2009; 41:342-7.
60. Gordon ED, Simpson LJ, Rios CL, Ringel L, Lachowicz-Scroggins ME, Peters MC, et al. Alternative splicing of interleukin-33 and type 2 inflammation in asthma. Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):8765-70. doi: 10.1073/pnas.1601914113.
61. Long X, Daya M, Zhao J, Rafaels N, Liang H, Potee J, et al. The role of ST2 and ST2 genetic variants in schistosomiasis. J Allergy Clin Immunol. 2017 Feb 9. pii: S0091-6749(17)30215-4. doi: 10.1016/j.jaci.2016.12.969.
62. Kouriba B, Chevillard C, Bream JH, Argiro L, Dessein H, Arnaud V, et al. Analysis of the 5q31-q33 locus shows an association between IL13-1055C/T IL-13-591A/G polymorphisms and Schistosoma haematobium infections. J Immunol. 2005 May15;174(10):6274-81. PubMed PMID: 15879126.
63. van der Pouw Kraan TC, van Veen A, Boeije LC, van Tuyl SA, de Groot ER, Stapel SO, et al. An IL-13 promoter polymorphism associated with increased risk of allergic asthma. Genes Immun 1999; 1:61-5. PubMed PMID: 11197307.
64. Long X, Chen Q, Zhao J, Rafaels N, Mathias P, Liang H, et al. An IL-13 promoter polymorphism associated with liver fibrosis in patients with Schistosoma japonicum. PLoS One 2015; 10:e0135360. doi: 10.1371/journal.pone.0135360.
65. Figueiredo CA, Barreto ML, Alcantara-Neves NM, Rodrigues LC, Cooper PJ, Cruz AA, et al. Coassociations between IL10 polymorphisms, IL-10 production, helminth infection, and asthma/wheeze in an urban tropical population in Brazil. J Allergy Clin Immunol 2013; 131:1683-90. doi: 10.1016/j.jaci.2012.10.043.
66. Timmann C, Fuchs S, Thoma C, Lepping B, Brattig NW, Sievertsen J, et al. Promoter haplotypes of the interleukin-10 gene influence proliferation of peripheral blood cells in response to helminth antigen. Genes Immun 2004; 5:256-60. PubMed PMID: 15129234.
67. Karimabad MN, Arababadi MK, Hakimizadeh E, Daredori HY, Nazari M, Hassanshahi G, et al. Is the IL-10 promoter polymorphism at position -592 associated with immune system-related diseases? Inflammation 2013; 36:35-41. doi: 10.1007/s10753-012-9517-7.
68. Huang ZY, Cheng BJ, Wan Y, Zhou C. Meta-analysis of the IL-10 promoter polymorphisms and pediatric asthma susceptibility. Genet Mol Res 2016; 15. DOI: 10.4238/gmr.15028320.
69. Sharma S, Raby BA, Hunninghake GM, Soto-Quiros M, Avila L, Murphy AJ, et al. Variants in TGFB1, dust mite exposure, and disease severity in children with asthma. Am J Respir Crit Care Med 2009; 179:356-62. doi: 10.1164/rccm.200808-1268OC.
70. Costa RD, Figueiredo CA, Barreto ML, Alcantara-Neves NM, Rodrigues LC, Cruz AA, et al. Effect of polymorphisms on TGFB1 on allergic asthma and helminth infection in an African admixed population. Ann Allergy Asthma Immunol 2017; 118:483-8 e1. doi: 10.1016/j.anai.2017.01.028.
71. Bottema RW, Kerkhof M, Reijmerink NE, Koppelman GH, Thijs C, Stelma FF, et al. X-chromosome Forkhead Box P3 polymorphisms associate with atopy in girls in three Dutch birth cohorts. Allergy 2010; 65:865-74. doi: 10.1111/j.1398-9995.2009.02291.x.
72. Bottema RW, Kerkhof M, Reijmerink NE, Thijs C, Smit HA, van Schayck CP, et al. Gene-gene interaction in regulatory T-cell function in atopy and asthma development in childhood. J Allergy Clin Immunol 2010; 126:338-46, 46 e1-10. doi: 10.1016/j.jaci.2010.04.024.
73. Geri G, Rabbat A, Mayaux J, Zafrani L, Chalumeau-Lemoine L, Guidet B, et al. *Strongyloides stercoralis* hyperinfection syndrome: a case series and a review of the literature. Infection. 2015 Dec;43(6):691-8. doi: 10.1007/s15010-015-0799-1.
74. Cruz AA, Lima F, Sarinho E, Ayre G, Martin C, Fox H, et al. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patient at risk of geohelminth infection. Clin Exp Allergy. 2007 Feb;37(2):197-207.
75. Sabin EA, Araujo MI, Carvalho EM, Pearce EJ. Impairment of tetanus toxoid-specific Th1-like immune responses in humans infected with *Schistosoma mansoni*. J Infect Dis. 1996 Jan;173(1):269-72. PubMed PMID: 8537675.
76. Esen M, Mordmüller B, de Salazar PM, Adegnika AA, Agnandji ST, Schaumburg F, et al. Reduced antibody responses against Plasmodium falciparum vaccine candidate antigens in the presence of Trichuris trichiura. Vaccine. 2012 Dec 14;30(52):7621-4. doi: 10.1016/j.vaccine.2012.10.026.
77. Labeaud AD, Malhotra I, King MJ, King CL, King CH. Do antenatal parasite infections devalue childhood vaccination? PLoS Negl Trop Dis. 2009 May 26;3(5):e442. doi: 10.1371/journal.pntd.0000442.
78. Wammes LJ, Hamid F, Wiria AE, May L, Kaisar MM, Prasetyani-Gieseler MA, et al. Community deworming alleviates geohelminth-induced immune hyporesponsiveness. Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):12526-12531. doi: 10.1073/pnas.1604570113.
79. Babu S, Nutman TB. Helminth-Tuberculosis Co-infection: An Immunologic Perspective. Trends Immunol. 2016 Sep;37(9):597-607. doi: 10.1016/j.it.2016.07.005.
80. Wiria AE, Djuardi Y, Supali T, Sartono E, Yazdanbakhsh M. Helminth infection in populations undergoing epidemiological transition: a friend or foe? Semin Immunopathol 2012; 34: 889–901. doi: 10.1007/s00281-012-0358-0.
81. Aravindhan V, Mohan V, Surendar J, Muralidhara Rao M, Pavankumar N, Deepa M, et al. Decreased prevalence of lymphatic filariasis among diabetic subjects associated with a diminished pro-inflammatory cytokine response (CURES 83). PLoS Negl Trop Dis. 2010 Jun 15;4(6):e707. doi: 10.1371/journal.pntd.0000707.
82. Chen Y, Lu J, Huang Y, Wang T, Xu Y, Xu M, et al. Association of previous schistosome infection with diabetes and metabolic syndrome: a cross-sectional study in rural China. J Clin Endocrinol Metab. 2013 Feb;98(2):E283-7. doi: 10.1210/jc.2012-2517.
83. Wiria AE, Wammes LJ, Hamid F, Dekkers OM, Prasetyani MA, May L, et al. Relationship between carotid intima media thickness and helminth infections on Flores Island, Indonesia. PLoS One. 2013;8(1):e54855. doi: 10.1371/journal.pone.0054855.
84. Correale J, Farez MF. The impact of parasite infections on the course of multiple sclerosis. J Neuroimmunol. 2011 Apr;233(1-2):6-11. doi: 10.1016/j.jneuroim.2011.01.002.
85. Weinstock JV, Elliott DE. Translatability of helminth therapy in inflammatory bowel diseases. Int J Parasitol. 2013 Mar;43(3-4):245-51. doi: 10.1016/j.ijpara.2012.10.016.
86. Summers RW, Elliott DE, Urban JF Jr, Thompson RA, Weinstock JV. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology. 2005 Apr;128(4):825-32.
87. Bourke CD, Mutapi F, Nausch N, Photiou DM, Poulsen LK, Kristensen B, et al. Trichuris suis ova therapy for allergic rhinitis does not affect allergen-specific cytokine responses despite a parasite-specific cytokine response. Clin Exp Allergy. 2012 Nov;42(11):1582-95. doi: 10.1111/j.1365-2222.2012.04063.x.
88. Croese J, O'neil J, Masson J, Cooke S, Melrose W, Pritchard D, et al. A proof of concept study establishing *Necator americanus* in Crohn's patients and reservoir donors. Gut. 2006 Jan;55(1):136-7. doi: 10.1136/gut.2005.079129.
89. Daveson AJ, Jones DM, Gaze S, McSorley H, Clouston A, Pascoe A, et al. Effect of hookworm infection on wheat challenge in celiac disease - a randomized double-blinded placebo controlled trial. PLoS One. 2011 Mar 8;6(3):e17366. doi: 10.1371/journal.pone.0017366.
90. Feary JR, Venn AJ, Mortimer K, Brown AP, Hooi D, Falcone FH, et al. Experimental hookworm infection: a randomized placebo-controlled trial in asthma. Clin Exp Allergy. 2010 Feb;40(2):299-306. doi: 10.1111/j.1365-2222.2009.03433.x.
91. Helmby H. Human helminth therapy to treat inflammatory disorders - where do we stand? BMC Immunol. 2015 Mar 26;16:12. doi: 10.1186/s12865-015-0074-3.
92. Nascimento Santos L, Carvalho Pacheco LG, Silva Pinheiro C, Alcantara-Neves NM. Recombinant proteins of helminths with immunoregulatory properties and their possible therapeutic use. Acta Trop. 2017 Feb;166:202-211. doi: 10.1016/j.actatropica.2016.11.016.
93. Steinfelder S, O'Regan NL, Hartmann S. Diplomatic Assistance: Can Helminth-Modulated Macrophages Act as Treatment for Inflammatory Disease? PLoS Pathog. 2016 Apr 21;12(4):e1005480. doi: 10.1371/journal.ppat.1005480.
94. Hanski I, von Hertzen L, Fyhrquist N, Koskinen K, Torppa K, Laatikainen T, et al. Environmental biodiversity, human microbiota, and allergy are interrelated. Proc Natl Acad Sci U S A. 2012 May 22;109(21):8334-9. doi:10.1073/pnas.1205624109.
95. Caraballo L, Zakzuk J, Lee BW, Acevedo N, Soh JY, Sánchez-Borges M, et al. Particularities of allergy in the Tropics. World Allergy Organ J. 2016 Jun 27;9:20. doi: 10.1186/s40413-016-0110-7.
96. Cattadori IM, Sebastian A, Hao H, Katani R, Albert I, Eilertson KE, Kapur V, Pathak A, Mitchell S. Impact of Helminth Infections and Nutritional Constraints on the Small Intestine Microbiota. PLoS One. 2016 Jul 20;11(7):e0159770. doi: 10.1371/journal.pone.0159770.
97. House JS, Wyss AB, Hoppin JA, Richards M, Long S, Umbach DM, et al. Early-life farm exposures and adult asthma and atopy in the Agricultural Lung Health Study. J Allergy Clin Immunol. 2017 Jul;140(1):249-256.e14. doi: 10.1016/j.jaci.2016.09.036.
98. Briggs N, Weatherhead J, Sastry KJ, Hotez PJ. The Hygiene Hypothesis and Its Inconvenient Truths about Helminth Infections. PLoS Negl Trop Dis. 2016 Sep 15;10(9):e0004944. doi: 10.1371/journal.pntd.0004944.
99. Garg SK, Croft AM, Bager P. Helminth therapy (worms) for induction of remission in inflammatory bowel disease. Cochrane Database Syst Rev. 2014 Jan 20;(1):CD009400. doi: 10.1002/14651858.CD009400.pub2.